Caremo Honored as One of the "Top 50 Chinese Pharmaceutical R&D Enterprises (2022-2023)"

July 4 – The "2022-2023 China Pharmaceutical Industry Most Influential Rankings" ceremony, hosted by the China Chamber of Commerce for Pharmaceutical Industry (CCPI), concluded successfully. Twelve authoritative industry rankings were officially unveiled, including the "Top 100 Chinese Pharmaceutical Manufacturers" and "Top 50 Chinese Pharmaceutical R&D Enterprises". This year, Caremo secured its position in the "Top 50 Chinese Pharmaceutical R&D Enterprises (2022-2023)", reflecting its strong technical prowess and industry-leading innovation capabilities.

The "China Pharmaceutical Industry Most Influential Rankings", organized by the China Chamber of Commerce for Pharmaceutical Industry (CCCPI), has become one of the most authoritative industry benchmarks in China’s pharmaceutical sector. To recognize excellence, establish benchmarks, and drive industry progress, the CCCPI leveraged its decades of expertise and industry networks to convene a panel of top-tier domestic experts for rigorous evaluation. The rankings adhered to principles of open nomination process, data-driven evaluation, rigorous screening, and impartial selection, collaborating with leading domestic media outlets. The 2022-2023 Most Influential Rankings were designed to amplify the impact of award-winning enterprises and individuals, setting standards for innovation and leadership in the pharmaceutical field.

Dedication and perseverance will always be rewarded by time and effort. Since its establishment, Caremo has remained steadfast in its corporate mission—“Born for Health, Empowered for Innovation”—by leveraging core technologies to integrate “innovative drugs + generic drugs” across the entire development lifecycle. Adopting a dual-drive strategy of R&D and industrialization, the company aligns research innovation with industrial goals, delivering customized R&D and industrialization solutions tailored to diverse client needs.

This accolade recognizes Caremo’s technical expertise, professional excellence, and innovative capabilities, while further motivating the company to advance its ambitions. Moving forward, Caremo will collaborate with global biotech and pharmaceutical partners across the entire R&D value chain—from target validation to commercialization—by addressing differentiated client demands through flexible collaboration models. The company aims to establish a comprehensive, end-to-end drug discovery and production service platform, providing full-spectrum technological and industrial support to empower the global biopharmaceutical sector.